On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral GLP-1R agonist, Rybelsus, ...

Over the past few days at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) 2024 in Chicago, US, the ...

The study will evaluate the company’s Gen-3 Halo headset as an at-home treatment for mild traumatic brain injury.

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Otsuka has reported positive interim results from its Phase III trial evaluating sibeprenlimab, a treatment for adults with ...

During IDWeek 2024 in the US, novel antimicrobials in the development pipeline that are poised to make a difference were ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Galderma has reported positive data from a Phase III clinical trial of RelabotulinumtoxinA for treating frown lines and ...

Madrigal Pharmaceuticals has finished enrolling patients in a trial of Rezdiffra, a drug candidate for compensated NASH ...

The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with type 2 ...

Zymeworks has dosed the first subject in a Phase I trial of ZW171 to treat ovarian cancer, non-small cell lung cancer and ...

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine ...